{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020869","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.087518+00:00","generated_at":"2026-06-15T04:49:46.357574+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Candel Therapeutics Q1 net loss $8.8M; cash runway into Q2 2024; fast track for CAN-2409 in NSCLC","bullets":["Net loss of $8.8M in Q1 2023 vs $0.9M in Q1 2022; includes $0.8M other income from warrant liability change.","Cash and equivalents $59.3M; expected to fund operations into Q2 2024.","FDA granted fast track designation for CAN-2409 in stage III/IV NSCLC resistant to PD-(L)1 therapy.","Paused enrollment in phase 2 pancreatic cancer trial pending additional funding; initial data still expected Q4 2023.","Upcoming data: CAN-3110 at ASGCT (May 19) and CAN-2409 NSCLC trial-in-progress at ASCO (June 4)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020869","json":"https://secwatch.observer/filing/0000950170-23-020869.json","markdown":"https://secwatch.observer/filing/0000950170-23-020869.md","text":"https://secwatch.observer/filing/0000950170-23-020869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023020869/0000950170-23-020869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023020869/cadl-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:49:46.357574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21618535208640c84331432754c46346c21e61c7","claim":"Candel Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $8.8 million.","evidence_excerpt":"Net loss for the first quarter of 2023 was $8.8 million compared to a net loss of $0.9 million for the first quarter of 2022, and included net other income of $0.8 million and $8.1 million, respectively, primarily related to the change in the fair value of the Company’s warrant liability.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023020869/0000950170-23-020869-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the first quarter of 2023 was $8.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}